Business Context and Reporting Period
Company: Moderna, Inc. (MRNA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Moderna is a biotechnology company focused on mRNA medicines. As of December 31, 2025, the company had three commercial products: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine). The company maintains a diverse pipeline of 35 development programs across infectious disease, oncology, and rare disease franchises.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $1,944 | $3,236 | (40)% |
| Net Product Sales | $1,818 | $3,109 | (42)% |
| Net Loss | $(2,822) | $(3,561) | 21% improvement |
| Loss Per Share (Diluted) | $(7.26) | $(9.28) | - |
| Operating Expenses | $5,018 | $7,181 | (30)% |
| Research & Development | $3,132 | $4,543 | (31)% |
| Cash, Cash Equivalents & Investments | $8,135 | $9,519 | (15)% |
| Working Capital | $4,557 | $5,893 | (23)% |
Debt & Liquidity: In November 2025, the company entered into a $1.5 billion credit facility. As of December 31, 2025, $600 million was drawn under the initial term loan. The company reported a net cash outflow from operating activities of $1.9 billion for the year.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 40% year-over-year, primarily driven by a 42% drop in net product sales due to lower COVID vaccine demand across all regions. RSV sales remained minimal ($8 million).
- Cost Reductions: Operating expenses decreased 30% to $5.0 billion. R&D expenses fell 31% due to the wind-down of large Phase 3 respiratory programs and portfolio prioritization. SG&A expenses decreased 13% due to cost discipline.
- Inventory Write-downs: Inventory write-downs in Cost of Sales were $291 million in 2025, a significant reduction from $495 million in 2024, though still driven by excess inventory and shelf-life expiration.
- Manufacturing Expansion: The company completed the acquisition of its Moderna Technology Center (MTC) in Norwood, MA, in December 2024. New manufacturing facilities in the UK, Canada, and Australia became fully licensed and operational in 2025.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2026 Expectations: Management expects revenue growth in 2026 driven by the full-year impact of long-term government partnerships (UK, Canada, Australia) and continued uptake of mNEXSPIKE in the U.S. retail channel.
- Cost Efficiency: The company plans to further reduce costs in 2026 and 2027, leveraging AI and digital tools to improve efficiency across manufacturing and R&D.
- Pipeline Milestones: Anticipated pivotal data readouts in 2026 for oncology (intismeran autogene), rare disease, and infectious disease portfolios. The FDA accepted the BLA for the seasonal flu vaccine (mRNA-1010) with a PDUFA goal date of August 5, 2026.
Key Risks and Contingencies
- Regulatory Uncertainty: Changes in FDA policies and ACIP recommendations regarding vaccine eligibility and composition could impact demand and approval timelines.
- Competition: Intense competition in the vaccine market, particularly from Pfizer/BioNTech for COVID and Pfizer/GSK for RSV. Moderna faces challenges in gaining market share in markets where competitors have established contracts.
- Profitability: The company incurred net losses in 2025 and 2024 and expects to incur additional losses in the future. Long-term sustainable profitability is not guaranteed.
- Legal Proceedings: Ongoing patent litigation with Pfizer/BioNTech, Arbutus, GSK, and others regarding mRNA platform and lipid nanoparticle technologies. Outcomes are uncertain and could result in significant damages or injunctions.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of the decline in COVID vaccine demand and the actual uptake of mNEXSPIKE in the U.S. retail channel versus government contracts.
- Flu Vaccine Approval: Monitor the FDA's decision on the mRNA-1010 seasonal flu vaccine BLA (PDUFA date: August 5, 2026) and the regulatory pathway for the flu+COVID combination vaccine (mRNA-1083).
- Cost Structure: Assess whether the company can maintain the 30% reduction in operating expenses while advancing late-stage clinical trials for oncology and rare disease candidates.
- Patent Litigation: Track the status of key patent disputes, particularly the Pfizer/BioNTech litigation in the UK and US, and the Arbutus/Genevant trials scheduled for 2026.
- Cash Burn Rate: Evaluate the sufficiency of the $8.1 billion cash position and the $1.5 billion credit facility to fund operations through the next 12 months given the continued net cash outflow from operations.
